Skip to main content

Peanut Allergy clinical trials at UCSF
4 in progress, 1 open to new patients

  • PALISADE Follow-on Study (ARC004)

    open to eligible people ages 4-55

    The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.

    San Francisco, California and other locations

  • AR101 Real-World Open-Label Extension Study

    Sorry, accepting new patients by invitation only

    This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.

    San Francisco, California and other locations

  • Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

    Sorry, accepting new patients by invitation only

    The purpose of this study is to assess AR101's safety and tolerability over an extended dosing period.

    San Francisco, California and other locations

  • Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

    Sorry, in progress, not accepting new patients

    This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT ™) regimen in peanut-allergic children.

    San Francisco, California and other locations